Off-label drug use: the need for clear national guidance
In October, twelve NHS clinical commissioning groups across northeast England and Cumbria agreed a policy to offer patients in the region with wet (neovascular) age-related macular degeneration the choice of ‘off-label’ use of bevacizumab (Avastin) as preferred treatment, with potential …